This is a renewal application for continued research in cancer management as a Member Institution of the Southwest Oncology Group.
The specific aims are to (1) conduct single and multiple disciplinary clinical trials as described in Group protocols, (2) conduct laboratory studies, single disciplinary and multiple disciplinary pilot studies that may lead to Group studies; emphasis will be placed upon clonogenic assay, cancer of the lung, head and neck, malignant melanoma and genitourinary neoplasms, (3) educate physicians, nurses, fellows, houseofficers, and allied health professionals as to methods of procedure in clinical trials and information gained by participation in the Group, (4) participate in scientific and administrative activities of the Group, and (5) participate in the distributive data management system. Investigators participating include five Medical Oncologists, three Hematologists, four Therapeutic Radiologists, three Surgeons, three Pathologists, three nurse Oncologists, one Urologist and one Neurosurgeon. Between 200-250 patients will be entered on Group protocols and 50-100 patients will be entered on Group related pilot projects annually. Continued improvements will be made in basic techniques and clinical applications of clonogenic assay. The research plan is designed to achieve these aims through the coordinated use of multiple disciplinary activities.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA004915-26
Application #
3555819
Study Section
Cancer Clinical Investigation Review Committee (CCI)
Project Start
1978-01-01
Project End
1987-12-31
Budget Start
1985-01-01
Budget End
1985-12-31
Support Year
26
Fiscal Year
1985
Total Cost
Indirect Cost
Name
Henry Ford Health System
Department
Type
DUNS #
City
Detroit
State
MI
Country
United States
Zip Code
48202
Tomblyn, Michael B; Goldman, Bryan H; Thomas Jr, Charles R et al. (2012) Cetuximab plus cisplatin, irinotecan, and thoracic radiotherapy as definitive treatment for locally advanced, unresectable esophageal cancer: a phase-II study of the SWOG (S0414). J Thorac Oncol 7:906-12
Rivkin, Saul E; Green, Stephanie J; Lew, Danika et al. (2003) Adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil, vincristine, and prednisone compared with single-agent L-phenylalanine mustard for patients with operable breast carcinoma and positive axillary lymph nodes: 20-year results of Cancer 97:21-9
Rivkin, S E; Green, S; O'Sullivan, J et al. (1996) Adjuvant CMFVP versus adjuvant CMFVP plus ovariectomy for premenopausal, node-positive, and estrogen receptor-positive breast cancer patients: a Southwest Oncology Group study. J Clin Oncol 14:46-51
Rivkin, S E; Green, S; Metch, B et al. (1994) Adjuvant CMFVP versus tamoxifen versus concurrent CMFVP and tamoxifen for postmenopausal, node-positive, and estrogen receptor-positive breast cancer patients: a Southwest Oncology Group study. J Clin Oncol 12:2078-85
Hayden, K A; Moinpour, C M; Metch, B et al. (1993) Pitfalls in quality-of-life assessment: lessons from a Southwest Oncology Group breast cancer clinical trial. Oncol Nurs Forum 20:1415-9
Jenkins, T R; Tangen, C; Macdonald, J S et al. (1993) A phase II trial of piroxantrone in adenocarcinoma of the pancreas. A Southwest Oncology Group study. Invest New Drugs 11:329-31
Chapman, R; Crowley, J; Lucas, J G et al. (1993) Mitogauzone, cisplatin, and vinblastine in advanced non-small cell lung cancer: a Southwest Oncology Group study. Invest New Drugs 11:91-2
Saeed, S M; Stock-Novack, D; Pohlod, R et al. (1991) Prognostic correlation of plasma cell acid phosphatase and beta-glucuronidase in multiple myeloma: a Southwest Oncology Group study. Blood 78:3281-7
Lamm, D L; Blumenstein, B A; Crawford, E D et al. (1991) A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guerin for transitional-cell carcinoma of the bladder. N Engl J Med 325:1205-9
Von Hoff, D D; Green, S; Alberts, D S et al. (1991) Phase II study of fludarabine phosphate (NSC-312887) in patients with advanced endometrial cancer. A Southwest Oncology Group Study. Am J Clin Oncol 14:193-4

Showing the most recent 10 out of 23 publications